Altimmune Inc (ALT)
4.23
+0.05
(+1.20%)
USD |
NASDAQ |
Mar 23, 12:40
Key Stats
Price and Performance | |
---|---|
Market Cap | 208.45M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -40.20% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 1.125 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.85% |
News
Headline
Wire
Time (ET)
MT Newswires
03/22 07:25
SA Breaking News
03/21 18:40
SA Breaking News
03/21 10:03
Globe Newswire
03/21 07:00
SA Breaking News
03/10 15:00
Globe Newswire
02/28 07:00
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
05/12/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
05/12/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
02/28/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
02/28/2023 | -- | Results | Q4 2022 | -0.44 | -0.54 | 17.91% | |
11/10/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
11/10/2022 | -- | Results | Q3 2022 | -0.48 | -0.51 | 5.42% | |
08/11/2022 | -- | Results | Q2 2022 | -0.42 | -0.50 | 15.15% | |
08/11/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines. |
URL | https://www.altimmune.com |
Investor Relations URL | https://ir.altimmune.com/ |
HQ State/Province | Maryland |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 12, 2023 (est.) |
Last Earnings Release | Feb. 28, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jan. 20, 2017 |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | Jan. 20, 2017 |
Yield (TTM) | 0% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | 0.00% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 22, 2023.
Fundamentals
Revenue (TTM) | -0.068M |
Total Expenses (TTM) | 87.67M |
Net Income (TTM) | -84.71M |
Total Assets (Quarterly) | 206.93M |
Total Liabilities (Quarterly) | 21.64M |
Shareholders Equity (Quarterly) | 185.29M |
Cash from Operations (TTM) | -62.59M |
Cash from Investing (TTM) | -73.40M |
Cash from Financing (TTM) | 56.78M |
Ratings
Profile
Edit
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines. |
URL | https://www.altimmune.com |
Investor Relations URL | https://ir.altimmune.com/ |
HQ State/Province | Maryland |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 12, 2023 (est.) |
Last Earnings Release | Feb. 28, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jan. 20, 2017 |
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
ALT Tweets |